<code id='876D9D04A5'></code><style id='876D9D04A5'></style>
    • <acronym id='876D9D04A5'></acronym>
      <center id='876D9D04A5'><center id='876D9D04A5'><tfoot id='876D9D04A5'></tfoot></center><abbr id='876D9D04A5'><dir id='876D9D04A5'><tfoot id='876D9D04A5'></tfoot><noframes id='876D9D04A5'>

    • <optgroup id='876D9D04A5'><strike id='876D9D04A5'><sup id='876D9D04A5'></sup></strike><code id='876D9D04A5'></code></optgroup>
        1. <b id='876D9D04A5'><label id='876D9D04A5'><select id='876D9D04A5'><dt id='876D9D04A5'><span id='876D9D04A5'></span></dt></select></label></b><u id='876D9D04A5'></u>
          <i id='876D9D04A5'><strike id='876D9D04A5'><tt id='876D9D04A5'><pre id='876D9D04A5'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:186
          Photography of the US department of health and human services in Silver Spring MD
          Manuel Balce Ceneta/AP

          An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

          Triple-check your data or we’ll reject your device, the FDA warned.

          advertisement

          The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          Readout Newsletter: What happened with Sarepta's Duchenne data
          Readout Newsletter: What happened with Sarepta's Duchenne data

          AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          UnitedHealth, Optum discontinue NaviHealth name

          MarkLennihan/APUnitedHealthGroupandOptumaregettingridofthenameoftheirtech-drivencaremanagementcompan